Advertisement
(Photo: http://www.newscom.com/cgi-bin/prnh/20081113/NETH122 )
During the recognition presentation, Dr. Jennifer Hunt, head of surgicalpathology at the Cleveland Clinic stated, "When we're talking about tumors,we're talking about what information can we gain about that tumor to guide anddirect therapy, prognosis, diagnostics. We believe this technology to be agame changer. It will take personalized medicine to an entirely new level.This is not a step, but a leap. Being able to analyze multiple markers in asingle cell to understand the behavior of actual signaling pathways willsignificantly aid in disease diagnosis and therapy development." Dr. Hunt wenton to add, "I expect that this technology will be rapidly adopted across thefield of pathology."
Advertisement
The list of devices and technologies was selected by a panel of physiciansand scientists affiliated with the Cleveland Clinic, and was unveiled duringthe annual Medical Innovation Summit this week.
"We are honored and grateful that this technology was recognized by theClinic," says George Abe, CEO of CRi. "We are dedicated to developingcomprehensive solutions that will help produce breakthroughs in biomedicalresearch and medical care."
As biological imaging becomes more about studying complex systems ratherthan single events, CRi's Nuance system allows users to monitor more than oneevent or target at a time. The system produces clear and accurate unmixedimages from a multi-label tissue section, whether the tissue is labeled forcellular, nuclear, or membrane markers that overlap spatially or spectrally.
"Our Nuance technology is like enabling a colorblind person to see colorfor the first time," adds Clifford Hoyt, Chief Technology Officer of CRi."Among other things, it can be used by both pre-clinical and clinical researchscientists to reveal new data to expedite targeted therapies, and byphysicians for personalized treatment."
Four major criteria served as the basis for qualifying and selectingCleveland Clinic's Top 10 Medical Innovations. To receive consideration, anominated innovation was required to: have significant potential for short-term clinical impact, have a high probability of success, be on the market orclose to being introduced, and have sufficient data available to support itsnomination.
Cambridge Research & Instrumentation, Inc (CRi) is a Boston-basedbiomedical imaging company providing innovative optical imaging solutions formore than 20 years. CRi's multidisciplinary team is dedicated to providingcomprehensive solutions that enable customers to produce breakthroughs inresearch and medical care. CRi technology helps extract new disease-specificinformation from biological and clinical samples in the physiological,morphological, and biochemical context of intact tissues and organisms.
With over 80 patents pending and issued, CRi's award-winning innovationsare being utilized around the world in a wide range of settings, ranging fromacademic researcher to pharmaceutical drug development to clinical medicine.CRi is headquartered in Woburn, Massachusetts, and operates a state-of-the-artmanufacturing facility and is able to rapidly design and manufacture system-level solutions for a variety of growing market applications.
Visit http://www.cri-inc.com/nuance to find out more about the Nuancesystem.For more information visit our website at www.cri-inc.com or contact: Ross Nakatsuji CRi Marketing/Sales Group Leader 35-B Cabot Road, Woburn, MA 01801 USA (P) 1-781-935-9099, extension 177, (C) 1-781-405-4000, (E) [email protected]
SOURCE Cambridge Research & Instrumentation, Inc.
